Drug name - Winlevi

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8143240 SUN PHARM 17α, 21-dihydroxypregnene esters as antiandrogenic agents
Jan, 2023

(a month from now)

US9211295 SUN PHARM 17 alpha, 21-dihydroxypregnene esters as antiandrogenic agents
Jul, 2023

(7 months from now)

US8865690 SUN PHARM 17alfa, 21-dihydroxypregnene esters as antiandrogenic agents
Jul, 2023

(7 months from now)

US9486458 SUN PHARM Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives
Jul, 2028

(5 years from now)

US10159682 SUN PHARM Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives
Aug, 2028

(5 years from now)

US11207332 SUN PHARM Enzymatic process for obtaining 17 α-monoesters of cortexolone and/or its 9,11-dehydroderivatives
Nov, 2028

(5 years from now)

US9433628 SUN PHARM Enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivatives
Feb, 2029

(6 years from now)

US8785427 SUN PHARM Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives
Jul, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 26, 2025

Drugs and Companies using CLASCOTERONE ingredient

Market Authorisation Date: 26 August, 2020

Treatment: Method of treating acne vulgaris with topically applied cortexolone 17a-propionate; Method of treating acne vulgaris with topically applied cortexolone 17alpha-propionate

Dosage: CREAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
1% CREAM;TOPICAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.

Other things you might be interested in